


# GNIPST BULLETIN 2024

(Pharmacy)



**VOLUME-1, ISSUE- 4**



**Special Edition**

*Sneak Peak  
on  
KC High School*

**Check out the Special  
Attraction Section**



# Table of Contents

**1****Message from Director and Principal**

2

**2****Recent Researches**

3-4

**3****New Drug Approvals**

5

**4****Clinical Trial News**

6-7

**5****Disease Outbreak News**

8

**6****Campus News**

9

**7****Special Attraction**

10-11

**8****Game Time**

12



### MESSAGE FROM HONORABLE DIRECTOR

I extend my heartfelt greetings to you all at Guru Nanak Institute of Pharmaceutical Science and Technology, we are committed to fostering an environment of academic excellence, innovation, and holistic development.

believe in nurturing inquisitive minds, encouraging critical thinking, and developing skills of our beloved students.

As we gather to celebrate the vibrant festival of Durga Puja in this month, let us embrace the spirit of unity and devotion that this occasion embodies. This year, may the divine energy of Maa Durga inspire us to overcome challenges and foster harmony within our communities. Wishing you all a festive season filled with love, laughter, and the blessings of prosperity. May Maa Durga illuminate our paths and guide us towards a brighter future.

*Prof. (Dr.) Abhijit Sengupta*



### MESSAGE FROM HONORABLE PRINCIPAL

It is my immense pleasure to extend a warm greetings to you to Guru Nanak Institute of Pharmaceutical Science and Technology, Pharmacy. GNIPST is amongst the leading educational institutes of West Bengal aiming to provide quality pharmacy education to students.

As we approach the auspicious festivals of Durga Puja and Navratri in this month, let us take this opportunity to reflect on the values of strength, devotion, unity and ethics that these celebrations embody. These festivals not only honor the divine feminine but also inspire us to overcome challenges and seek inner strength. May the blessings of Maa Durga fill our hearts with courage and compassion. Wishing you all a joyful and meaningful celebration!

*Prof (Dr.) Lepamudra Datta*





## RECENT RESEARCHES



### New global guidance aims to curb antibiotic pollution from manufacturing



<https://www.who.int>

The World Health Organization (WHO) has published its first-ever guidance on antibiotic pollution from manufacturing. The new guidance on wastewater and solid waste management for antibiotic manufacturing sheds light on this important but neglected challenge ahead of the United Nations General Assembly (UNGA) High-Level Meeting on antimicrobial resistance (AMR) taking place on 26 September 2024. The emergence and spread of AMR caused by antibiotic pollution could undermine the effectiveness of antibiotics globally, including the medicines produced at the manufacturing sites responsible for the pollution. Despite high antibiotic pollution levels being widely documented, the issue is largely unregulated and quality assurance criteria typically do not address environmental emissions. In addition, once distributed, there is a lack of information provided to consumers on how to dispose of antibiotics when they are not used, for example, when they expire or when a course is finished but there is still antibiotic left over.

### Data show marked increase in annual cholera deaths



<https://www.who.int>

This WHO Medical Product Alert refers to one batch of falsified Oxymorphone Hydrochloride 40mg. The falsified product was detected in the unregulated supply chain in Finland and reported to WHO in July 2024 by the Finnish Medicines Agency (FIMEA). Oxymorphone Hydrochloride is a semi-synthetic opioid used to treat moderate to severe pain. Laboratory analysis of samples of the falsified product, however, found that the tablets contained metonitazene instead. Metonitazene is a potent psychoactive synthetic opioid drug, with no officially recognized or authorized medicinal or therapeutic use. It is under international control as a Schedule I narcotic drug following recommendations of the WHO Expert Committee on Drug Dependence in 2021.

### High-level mission to Sudan reaffirms WHO commitment, calls for urgent action to address and end the extreme health and humanitarian crisis



<https://www.who.int>

WHO Director-General Dr Tedros Adhanom Ghebreyesus and Regional Director Dr Hanan Balkhy yesterday concluded a two-day mission to Port Sudan, where they reaffirmed WHO's commitment to reaching all Sudanese in need and called on the international community to urgently act to end the extreme health and humanitarian crisis. During their visit, Dr Tedros and Dr Balkhy met with Sudanese leaders, including Lt. Gen. Abdul Fatah Al-Burhan, Chairman of Sudan's Transitional Sovereignty Council; Deputy Chairman of Sudan's Sovereignty Council Dr Malik Agar; and Federal Minister of Health Dr Haitham Mohamed Ibrahim Awadallah. The discussions centered on the devastating impact of the ongoing conflict and the critical need for unhindered humanitarian access to ensure that life-saving aid reaches all those in need, regardless of their location.





## RECENT RESEARCHES



**Get it right, make it safe!": WHO highlights safe diagnosis during global campaign for patient safety**

**READ MORE**

<https://www.who.int>

Recognizing the urgent need for a broad-based effort globally to reduce errors in medical diagnosis, the World Health Organization (WHO) is calling on all stakeholders to "Get it right, make it safe!" as part of the World Patient Safety Day campaign on 17 September. The theme 'improving diagnosis for patient safety' was selected in consultation with a wide range of stakeholders – from patients to policy-makers – to highlight how everyone has a vital role to play in reducing the risks and impact of errors in diagnosis. "The right diagnosis, at the right time, is the basis of safe and effective health care. By contrast, diagnostic errors can lead to serious harm, and even death," said WHO Director-General Dr Tedros Adhanom Ghebreyesus. "Reducing this risk takes collaboration between health workers and managers, policymakers and regulators, civil society and the private sector, and importantly, patients and their families."

**WHO at UNGA: Call for urgent, high-level action to address global scourge of antimicrobial resistance**

**READ MORE**

<https://www.who.int>

The World Health Organization (WHO) and partners will call on world leaders to address critical global health challenges, and invest in global public health, at meetings throughout the high-level week of the 79th session of the United Nations General Assembly (UNGA79), to be held in New York from 20 to 30 September 2024. The second High-Level Meeting on Antimicrobial Resistance (AMR) on 26 September 2024 will be the principal official, health-focused event during the UNGA high-level week. Without decisive action, such as that outlined in the final text of the draft political declaration for the meeting, AMR will cause even more global suffering, particularly in low- and middle-income countries. Antimicrobial resistance (AMR) occurs when bacteria, viruses, fungi and parasites no longer respond to medicines, making people sicker and increasing the spread of infections that are difficult to treat, leading to illness and deaths. The intergovernmental negotiations for the declaration were co-facilitated by Malta and Barbados. The first UN High-level Meeting on AMR took place in 2016.

**New global guidance puts forward recommendations for more effective and equitable clinical trial**

**READ MORE**

<https://www.who.int>

The World Health Organization (WHO) today released guidance to improve the design, conduct and oversight of clinical trials in countries of all income levels. This guidance aims to support stronger country-led research and development (R&D) ecosystems to advance health science so that new, safe and effective health interventions can be made more accessible and affordable globally for people everywhere, faster. For the first time, WHO offers recommendations for national health authorities, regulatory authorities, funders and others on how they can best facilitate clinical trials to generate evidence on health interventions. It addresses challenges such as poor trial design, limited diversity of participants, insufficient infrastructure and bureaucratic inefficiencies, which cost time, money and lives.



# NEW DRUG APPROVALS

SEPTEMBER 2024



## Ebglyss (lebrikizumab-lbkz) injection

- **Company:** Eli Lilly and Company
- **Date of Approval:** September 13, 2024
- **Treatment for:** Atopic Dermatitis

1

## Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) Injection

- **Company:** Genentech, Inc.
- **Date of Approval:** September 13, 2024
- **Treatment for:** Multiple Sclerosis

2

## Tecentriq Hybreza Injection

- **Company:** Genentech, Inc.
- **Date of Approval:** September 12, 2024

3

## Miplyffa (arimoclomol) Capsules

- **Company:** Zevra Therapeutics, Inc.
- **Date of Approval:** September 20, 2024
- **Treatment for:** Niemann-Pick Disease

4

## Cobenfy (xanomeline and trospium chloride) Capsules

- **Company:** Bristol-Myers Squibb Company
- **Date of Approval:** September 26, 2024
- **Treatment for:** Schizophrenia

5

## Flyrcado (flurpiridaz F 18) Injection

- **Company:** GE HealthCare
- **Date of Approval:** September 27, 2024
- **Treatment for:** Positron Emission Tomography Imaging

6

LEARN

MORE

<https://www.drugs.com/newdrugs.html>

# CLINICAL TRIAL NEWS



## 1. TCBP Announces First Patient Completed the Full Dose Regimen in ACHIEVE Clinical Trial

**EDINBURGH, Scotland, Sept. 12, 2024.** TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company"), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announces the first patient has completed the full dose regimen in the ACHIEVE Phase 2b trial ongoing in the UK with no drug related Adverse Events seen in any of the re start patients. As previously stated, patients are eligible to receive up to 4 total doses of TCB under the ACHIEVE protocol. Based on the amended dosing, this patient received approximately one billion cells in the TCB008 dosing regimen.



## 2. Insilico Medicine Reports Positive Phase IIa Results for ISM001-055, a Novel First-in-Class Drug Treatment for Idiopathic Pulmonary Fibrosis (IPF) Designed Using Generative AI




INSILICO MEDICINE

**CAMBRIDGE, Mass., Sept. 18, 2024.** Insilico Medicine, a clinical-stage generative AI-driven drug discovery company, announced positive preliminary results from its Phase IIa clinical trial evaluating ISM001-055. ISM001-055 is a first-in-class small molecule targeting TNK1 (Traf2- and Nck-interacting kinase) and was designed utilizing generative AI to treat idiopathic pulmonary fibrosis (IPF). The study met both its primary endpoint of safety and its secondary efficacy endpoints, demonstrating dose-dependent response in forced vital capacity (FVC), a critical measure of lung function in IPF patients.

## 3. Ascletois Enters the Obesity Drug Space with Announcement of Two Ongoing U.S. Phase I Clinical Trials Utilizing Its Small Molecule GLP-1R Agonist ASC30

**HONG KONG, Sept. 17, 2024.** Ascletois Pharma Inc. ("Ascletois") announces today completion of initial dosing in its two recently initiated U.S. Phase I clinical trials for ASC30, the first and only small molecule GLP-1 receptor (GLP-1R) agonist that can be dosed once monthly subcutaneously and once-daily orally for the treatment of obesity. Ascletois received clearance for its Investigational New Drug (IND) applications from the U.S. Food and Drug Administration (FDA) in July 2024 for ASC30 tablets and September 2024 for ASC30 injection. The Company expects topline data from both U.S. Phase I clinical trials in the first quarter of 2025.



## 4. Trishula Therapeutics Presents Positive Results from Phase I Trial of TTX-030 in First-Line Metastatic Pancreatic Cancer Patients



**SOUTH SAN FRANCISCO, Calif., Sept. 16, 2024.** Trishula Therapeutics, Inc., a clinical stage, privately held biotechnology company, today reported final results from a Phase 1 trial of TTX-030, a potential first-in-class, anti-CD39 antibody, in patients with first-line metastatic pancreatic cancer. Results were presented at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain.

## 5. Vico Therapeutics Announces Positive Interim Phase 1/2a Clinical Data of VO659 in Treatment of Huntington's Disease

**LEIDEN, Netherlands, Sept. 13, 2024.** Vico Therapeutics B.V., a clinical-stage genetic medicines company developing therapies for severe neurological diseases, today announced new positive interim data in Huntington's disease (HD) from the ongoing Phase 1/2a clinical trial of VO659, an investigational allele-preferential antisense oligonucleotide (ASO) therapy. Results will be highlighted in an oral presentation at the European Huntington's Disease Network's EHDN & Enroll-HD 2024 meeting on Friday, September 13, 2024 at 9:45 a.m. CET.



# CLINICAL TRIAL NEWS



## **6. Neurocrine Biosciences Provides Update on ERUDITE Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia**

**SAN DIEGO, Sept. 12, 2024.** Neurocrine Biosciences, Inc. today announced that its ERUDITE Phase 2 clinical study of investigational compound luvadaxistat (NBI-1065844) failed to meet its primary endpoint as a potential treatment to improve cognitive impairment in patients with schizophrenia.



## **7. Biolexis Unveils Promising Data with an Oral Weight Loss Drug: BLX-7006 Shows Significant Results in Preclinical Studies**



**LEHI, Utah., Sept. 12, 2024.** Biolexis Therapeutics, a biopharmaceutical company pioneering next-generation weight loss treatments, today announced the remarkable preclinical results of its oral small molecule GLP-1 agonist, BLX-7006. In a recent study, BLX-7006 demonstrated significant weight loss efficacy, establishing it as a potential breakthrough in the global fight against obesity.

## **8. Dupixent Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria**

**TARRYTOWN, N.Y. and PARIS, Sept. 11, 2024.** Regeneron Pharmaceuticals, Inc. and Sanofi today announced that a Dupixent (dupilumab) confirmatory Phase 3 trial (LIBERTY-CUPID Study C) met the primary and key secondary endpoints for the investigational treatment of patients with uncontrolled, biologic-naïve chronic spontaneous urticaria (CSU) receiving background therapy with antihistamines. CSU is a chronic skin condition that causes sudden and debilitating hives and persistent itch, which can impact quality of life. This positive trial confirms results from Study A, the first Phase 3 trial of Dupixent in this setting. Earlier this year, Japan was the first country in the world to approve and launch Dupixent for adult and adolescent CSU patients based on the results from Study A.



## **9. Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetes**



**INDIANAPOLIS, Sept. 10, 2024.** Eli Lilly and Company today announced detailed results from the QWINT-2 phase 3 trial evaluating once-weekly insulin efsitora alfa (efsitora) compared to once-daily insulin degludec in adults with type 2 diabetes using insulin for the first time (insulin naïve). The data were published in The New England Journal of Medicine (NEJM) and simultaneously presented today at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024.

## **10. First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma**

**HOUSTON, Sept. 9, 2024.** Moleculin Biotech, Inc., ("Moleculin" or the "Company"), a Phase 3 clinical-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced the enrollment and treatment of patients in an Investigator-initiated Phase 2 study evaluating WP1066 in combination with radiation therapy for the treatment of adults with glioblastoma (NU 21C06). The study is being conducted under Northwestern University's Investigative New Drug application (IND) which cross references the Company's own IND, which received clearance from the U.S. Food and Drug Administration (FDA) in April 2022. This trial is funded by the National Institutes of Health (NIH) and BrainUp, a non-profit organization dedicated to bringing awareness to brain cancer.



# DISEASE OUTBREAK NEWS



## 1. Marburg virus disease - Rwanda 30 September 2024

### Situation at a glance

On 27 September 2024, the Rwanda Ministry of Health announced the confirmation of Marburg virus disease (MVD). Blood samples taken from people showing symptoms were tested by real-time reverse transcription polymerase chain reaction (RT-PCR) at the National Reference Laboratory of the Rwanda Biomedical Center and were positive for Marburg virus. As of 29 September 2024, a total of 26 confirmed cases, including eight deaths have been reported. The cases are reported from seven of the 30 districts in the country. Among the confirmed cases, over 70% are healthcare workers from two health facilities in Kigali. The patients are being cared for in hospitals. Contact tracing is underway, with 300 contacts under follow-up. This is the first time MVD has been reported in Rwanda. The Government of Rwanda is coordinating the response with support from WHO and partners. There is currently no available treatment or vaccine for MVD. This is why it is important for people showing Marburg-like symptoms to seek care early for supportive treatment which can improve patient survival. WHO assesses the risk of this outbreak as very high at the national level, high at the regional level, and low at the global level.



<https://www.who.int/emergencies/disease-outbreak-news/item/2024-DON537>



<https://www.who.int/emergencies/disease-outbreak-news/item/2024-DON534>

## 2. Avian Influenza A(H9N2) - Ghana 20 September 2024

### Situation at a glance

On 26 August 2024, the International Health Regulations (IHR) National Focal Point (NFP) for Ghana notified the World Health Organization (WHO) regarding the country's first reported human case of infection with a zoonotic (animal) influenza virus. Subsequent laboratory tests confirmed the presence of the avian influenza A(H9N2) virus. According to epidemiological investigations, the patient, under five years old, had no known history of exposure to poultry or any sick person with similar symptoms prior to the onset of symptoms. The Ghanaian government has implemented a series of measures aimed at monitoring, preventing, and controlling the situation. According to the IHR (2005), a human infection caused by a novel influenza A virus subtype is an event that has the potential for high public health impact and must be notified to the WHO. Based on currently available information, WHO assesses the current risk to the general population posed by A(H9N2) viruses as low, but is continuing to monitor these viruses and the situation globally.



# Campus News



### MoU sign with University of Cyberjaya:

The signing of the Memorandum of Understanding (MoU) between GNPST and University of Cyberjaya took place during the international conference held on 1st September, 2024 at Dhono Dhanyo Auditorium, which signifies a significant step towards strengthening international cooperation in the pharmaceutical sector.



### National Seminar on IPR:

A National Seminar titled "IPR- Various forms and Techno-legal issues for patenting of inventions" with Mr. Anjan Sen as a speaker, is being organized by GNPST on 9th September, 2024. This seminar significantly enhanced the understanding of intellectual property rights including patents, trademarks, copyrights, and trade secrets, and equipped them with essential knowledge for innovation and entrepreneurship.



### International Conference (MIINDV):

FRONTIER AREAS OF MEDICAL / PHARMACEUTICAL SCIENCE AND TECHNOLOGY (1.9.24): GNPST in collaboration with Indian Pharmacy Graduates' Association (IPGA), Bengal Branch organized a International Conference on FRONTIER AREAS OF MEDICAL / PHARMACEUTICAL SCIENCE AND TECHNOLOGY, named as Make in India Initiative for New Drug and Vaccine on 1st September, 2024 at Dhono Dhanyo Auditorium. Some renowned speakers such as Prof Dr. David Whiteford (Vice Chancellor, University of Cyberjaya, Malaysia), Dr. Shyam Nandi (Deputy Director of ICMR, Pune), Mr. Sanjay Mishra (Plant Head, Cipla, Goa), Dr. Ashok Balaraman (Director of Research, University of Cyberjaya, Malaysia) Dr. Vijay Bhalla (Principal, SGT College of Pharmacy, SGT University, Gurgaon), Prof. (Dr.) Anirban Bhunia (Professor, Chemical Sciences, Bose Institute, Kolkata) delivered their valuable speech and enlightened the session.



### Campus to Career Seminar :

The final year students gained invaluable insights into various domains of Pharma market through an engaging panel discussion "Campus to Career". The Panel consisted of eminent Alumni Members.



### National Seminar on Plants as a Source of Drug and Nutrition:

Guru Nanak Institute of Pharmaceutical Science and Technology organized a National Seminar on "Plants as a Source of Drugs and Nutrition: The Past, Present, and Future", where we gained valuable insights from Dr. Subhalakshmi Ghosh, Director of Alona Life Sciences Pvt Ltd. and Alona Research and Diagnostic.



### Strength: The Message of The Upanishads

The Social Welfare Club and Nabachetana Yoga and Meditation Club of GNPST have initiated a 4-month course on Vedanta, commencing with an introductory session titled "Strength: The Message of The Upanishads," by Swami Sankarananda, International Vedanta Society, as the speaker.



### World Pharmacist Day (25.9.24) :

GNPST is thrilled to host a Digital Poster Making Competition in celebration of World Pharmacist Day 2024 in order to create awareness about the importance of Pharmacists and their immense contribution to society.



### Teachers' Day Celebration :

On the occasion of Teacher's day, our Final year students of all disciplines organized an event and celebrated the day with the faculty members.

GNPST BULLETIN 2024



# Durga Puja: A Festival of Triumph, Empowerment and Unity

Durga Puja, a major festival within Hinduism, is traditionally observed over ten days during the month September–October. It is especially celebrated in the regions of Bengal, Assam, and other eastern Indian regions and also some foreign countries. The festival commemorates the triumph of the goddess Durga over the demon king Mahishasura.



Durga Puja holds profound significance in various dimensions, both spiritual and cultural:

- **Spiritual Triumph:** The festival symbolizes the victory of good over evil, as it commemorates the goddess Durga's defeat of the demon king Mahishasura. This victory represents the triumph of righteousness and justice, inspiring devotees to overcome personal and societal challenges.
- **Cultural Heritage:** Durga Puja is a vital expression of Bengali culture and identity. It brings communities together, fostering social cohesion and collective celebration through elaborate rituals, art, music, and dance.
- **Feminine Empowerment:** The festival honors the divine feminine, or shakti, showcasing the strength and power of women. It encourages the recognition of female agency and resilience in both mythological and contemporary contexts.
- **Ritualistic Practices:** The various rituals and ceremonies performed during the festival, including the installation of idols, prayers, and cultural performances, provide spiritual enrichment and a sense of devotion among participants.
- **Community Engagement:** The festival fosters community spirit through collaboration in organizing events, decorating pandals, and participating in processions. This collective effort strengthens social bonds and enhances communal harmony.
- **Art and Creativity:** Durga Puja is a platform for artistic expression, showcasing intricate idol craftsmanship, elaborate pandal designs, and performances of traditional art forms. It highlights the rich cultural heritage and creativity of the region.



# A JOURNEY *Through Time*

## KANTAMARI CHURAMONI HIGH SCHOOL (H.S.)



**KANTAMARI CHURAMONI HIGH SCHOOL (H.S.)**

Kultali, South 24 Parganas



**KANTAMARI CHURAMONI HIGH SCHOOL** was established in 1962



• **Early Career and Education : Mr. Dipankar Mandal**

Mr. Dipankar Mandal began his educational journey as an Assistant Teacher at Kantamari Churimoni High School on July 15, 2005. He dedicated nearly a decade to teaching, transitioning to the role of Teacher-in-Charge on July 19, 2014, where he continued to inspire students and support the school community until November 16, 2019. His leadership journey culminated in his appointment as Headmaster on February 9, 2022, a role he has embraced with commitment and vision.

• **Kantamari Churimoni High School**

Kantamari Churimoni High School, established in 1962 and located in the rural Kultali block of South 24 Parganas, serves grades 1 to 4 and includes a pre-primary section. The school, managed by the Department of Education, operates in Bengali and has a co-educational setup. The school has focused not only on academic excellence but also on the holistic development of its students.



**Mr. Dipankar Mandal**  
HM of Kantamari Churamoni High School



Self - Defense workshop

In a poignant instance of social responsibility, Dipankar intervened in a case involving an underage girl who was forcefully married before completing her education. He took decisive action to ensure she finished her schooling, embodying the qualities of a compassionate leader and advocate for education.

• **Challenges and Innovations**

One of the most significant challenges Mr. Dipankar Mandal faced as Headmaster was the COVID-19 pandemic. During this uncertain time, he implemented innovative solutions to maintain educational engagement and community connection. Recognizing the strong maternal bond within families, he introduced "Mother-Teachers' Meetings," which replaced traditional Parents-Teachers Meetings, fostering a supportive environment that was well-received by the community.



Mothers' Teacher Meeting

• **Future Goals and Initiatives**

Looking ahead, Mr. Dipankar Mandal aims to reintroduce the Science stream at Kantamari Churimoni High School, a program that was discontinued in 2018. He believes that diversifying the curriculum is essential for providing students with comprehensive educational opportunities.

In response to societal needs, he has organized self-defense workshops for women, emphasizing the importance of empowerment and independence. Dipankar is committed to developing a long-term curriculum focused on women's empowerment and self-defense, ensuring that the community is equipped with essential skills for safety and confidence.



YES GIRL! YOU CAN!



# Game Time

## Pictionary Game

1. (🦵 - O - 🙏 - ZOLE) [Hints- PPI]
2. (G-🍌 -PI-🚲) [Hints- oral hypoglycemic agent]
3. (AL-🙏 -ZO-🐦) [Hints- Antidepressants]
4. (🚗 -CO-🐭 -IN) [Hints- Antibiotics]
5. (👁️ -🐝 - 🖐️ PRO- 🌀) [Hints- NSAIDS]

## Answer for Word Making

A	C	F	Y	U	O	H	L	G	D	E	W
P	H	A	R	M	A	C	O	I	D	G	Y
A	R	N	P	W	D	T	S	L	K	L	
R	O	A	S	S	A	Y	R	V	E	H	K
A	M	I	A	B	L	E	T	Q	F	L	I
C	A	O	S	Q	K	M	U	I	R	A	C
E	T	M	B	N	T	H	J	Q	X	H	
I	O	Y	V	W	F	N	O	T	Z	Y	K
A	G	R	A	N	U	L	E	S	O	R	D
M	R	C	Q	O	J	D	L	B	I	R	T
O	A	U	I	O	C	L	A	V	E	Y	F
I	P	R	T	H	J	T	A	V	L	W	H
W	H	I	S	T	A	M	I	N	E	B	J
D	Y	H	X	U	I	O	W	S	Q	Z	C

Shout out to the "Game Time" Winner of Volume 1, Issue 3 !



Debanjan Bhattacharya  
2nd year 3rd semester

Stay tuned for to the next edition for a shout out to fastest correct answers!

Submit your answer



SCAN  
ME

or

CLICK  
HERE



# Editorial Board

## Editor- in- Chief

*Prof. (Dr.) Abhijit Sengupta*

## Managing Editors

Prof. (Dr.) Lopamura Datta

## Associate Editors

Mr. Tushar Adhikari

Ms. Manjarima Ganguli

## Editorial Board Members

Mrs. Indrani Banerjee Chakraborty

Mr. Arpan Dutta

Ms. Ananya Chandra

Ms. Parnasree Chakraborty

Ms. Lopamudra Saha

Mr. Sarthak Saha



## COURSES OFFERED

### PHARMACY UG COURSES

- Bachelor of Pharmacy (B.Pharm)

### PHARMACY DIPLOMA COURSES

- Diploma in Pharmacy (D.Pharm)

### PHARMACY PG COURSES

- M.Pharm in Pharmaceutics
- M.Pharm in Pharmacology
- M.Pharm in Pharmaceutical Chemistry
- M.Pharm in Quality assurance
- M.Pharm in Regulatory Affairs
- M.Pharm in Pharmacognosy
- M.Pharm in Pharmaceutical Biotechnology



**Latest  
news**



[www.gnipst.ac.in](http://www.gnipst.ac.in)



[www.facebook.com](http://www.facebook.com)



[www.instagram.com](http://www.instagram.com)



[www.linkedin.com](http://www.linkedin.com)



[www.youtube.com](http://www.youtube.com)



[api.whatsapp.com](http://api.whatsapp.com)